



## **Synta Pharmaceuticals to Present at the BIO CEO & Investor Conference 2004**

February 20, 2004

LEXINGTON, MA - February 20, 2004 - Synta Pharmaceuticals Corp. today announced that Safi Bahcall, Ph.D., President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Wednesday, February 25, 2004 at 2:00 PM EST in the Park Avenue Suite North of the Waldorf-Astoria in New York, NY. Dr. Bahcall will provide a corporate overview and an update on Synta's pipeline.

The presentation will be webcast and can be accessed from Synta's website at <http://www.syntapharma.com/>. A replay of the presentation will be archived there after the event.

### **About Synta**

Synta Pharmaceuticals is an emerging pharmaceutical company focused on discovering, developing, and commercializing breakthrough products for severe medical conditions. Synta has a diverse pipeline of small-molecule therapeutics for the treatment of cancer and immune disorders, with its two most advanced products in Phase II clinical development. Synta developed as a buyout of the U.S. subsidiary of a large Japanese pharmaceutical company. As a result, Synta has an experienced and successful drug discovery team that has worked together for over ten years. All clinical candidates were developed by this team using Synta's chemistry-driven drug discovery platform. Synta fully owns all rights for all of its products. For more information, please see <http://www.syntapharma.com/>.